Concepedia

Mao Yin

MY

Statistics

Publications

16

Citations

624

H-Index

14

Active since

1958

Affiliations

Mersana Therapeutics (United States)(Current)

Michigan State University

Massachusetts General Hospital

Saint Louis University

Harvard University

Mao Yin is an author at Mersana Therapeutics (United States) specializing in pharmacy, antibody-drug conjugates, and pharmacology.

ORCID

Publications per year

1958–2023

16

Publications

16

A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak et al. · Cancer Research · 2015 · 100 citations

, , +17

Preparation and Characterization of Substituted Polylactides

Mao Yin, Gregory L. Baker · Macromolecules · 1999 · 96 citations

, , +12

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin et al. · Molecular Cancer Therapeutics · 2021 · 75 citations · Full text

, , +17

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy et al. · Molecular Cancer Therapeutics · 2021 · 48 citations · Full text

, , +17

BILE ACIDS

Theodore A. Mahowald, Mao Yin, John T. Matschiner et al. · Journal of Biological Chemistry · 1958 · 42 citations · Full text

1–5 of 16